Program ANR2021

Introduction to symposium

Angelika Eggert, Berlin, Germany

Introduction of new HR-NBL2-SIOPEN trial

Dominique Valteau-Couanet, Villejuif, France

Introduction to Current and Future COG High Risk Trials

Rochelle Bagatelle, Philadelphia, USA

Current international relapse concepts/early clinical trials

Lucas Moreno, Barcelona, Spain

Low and intermediate risk neuroblastoma

Barbara Hero, Cologne, Germany

MS1.1 Surviving High-Risk Neuroblastoma: A Preliminary Descriptive Report from Project LEAHRN (Late Effects After High-Risk Neuroblastoma)

Lisa Diller, Boston, USA

This session is sponsored by Villa Joep

Introduction to symposium

Olivier Delattre, Paris, France

Introduction on normal sympatho-adrenergic lineage development

Igor Adameyko, Stockholm, Sweden

MS2.1 Developmental and oncogenic programs in neuroblastomas dissected by single-cell analysis

Selina Jansky, Heidelberg, Germany

MS2.2 Single-cell RNA sequencing of human neuroblastoma reveals Schwann cell precursors as putative cancer stem cells

Thale Kristin Olsen, Stockholm, Sweden

MS2.3 Dissecting neuroblastoma tumor heterogeneity and cell plasticity by single cell RNAseq

Cecile Thirant, Paris, France

MS2.4 Drug resistance and phenotype of MES- and ADRN-type neuroblastoma cells faithfully reflect consecutive stages of normal adrenergic lineage development

Johan van Nes, Amsterdam, the Netherlands

This session is sponsored by Neuroblastoma UK

PA1.1 Relapsed/refractory pediatric neuroblastoma: excellent tolerability and sustained responses with temozolomide-based regimens

Lucy Métayer, Villejuif, France

PA1.2 Risk classification for patients with first recurrence of stage 4 neuroblastoma

Angela Ernst, Cologne, Germany

PA1.3 Randomized Phase II Trial of MIBG vs. MIBG/Vincristine/Irinotecan vs. MIBG/Vorinostat for Patients with Relapsed/Refractory Neuroblastoma: A Report from the New Approaches to Neuroblastoma Therapy

Steven DuBois, Boston, USA

PA1.4 Long Term Survival for Patients with Central Nervous System Metastases Following Treatment with Intraventricular Radiolabeled Omburtamab: Results of Trial 03-133

Kim Kramer, New York, USA

PA2.1 Contribution of TWIST1 in the aggressiveness of neuroblastoma by modulation of the tumor-stroma crosstalk

Maria-Vittoria Sepporta, Lausanne, Switzerland

PA2.2 Targeting Fatty Acid Transport in MYCN-amplified Neuroblastoma

Ling Tao, Houston, USA

PA2.3 MYCN regulates metabolism through vesicular transfer of glycolytic kinases

Alexia Tsakaneli, London, UK

PA2.4 Cellular and gene signatures of tumor-infiltrating dendritic cells and natural killer cells predict favorable clinical outcome of neuroblastoma

Ombretta Melaiu, Rome, Italy

PA3.1 Single cell transcriptome analysis decodes development trajectory of neural crest cells

Ran Yang, Shanghai, China

PA3.2 A single cell atlas of the developing murine adrenal gland

Evelyn Hanemaaijer, Utrecht, The Netherlands

PA3.3 ASCL1 activation by dephosphorylation can direct a genome-wide re-engagement of a latent differentiation programme in neuroblastoma

Lydia Parkinson, Cambridge, UK

PA3.4 The development of a human embryonic stem cell derived differentiation model to study normal and neuroblastoma development

Stéphane Van Haver, Ghent, Belgium

PA4.1 Natural history of ganglioneuroma (GN) and intermixed ganglioneuroblastoma (iGNB): An International Neuroblastoma Risk Group (INRG) project

Paola Angelini, Sutton, UK

PA4.2 Long-term health status of high-risk neuroblastoma survivors treated with high-dose chemotherapy and hematopoietic stem cell transplantation

Sandrine Haghiri, Villejuif, France

PA4.3 Neuroblastoma Patient-Derived Cell Lines and Xenografts in the COG/ALSF Childhood Cancer Repository

Kristyn McCoy, Lubbock, USA

PA4.4 The incidence of neuroblastoma cases before and after screening in Japan

Tomoko Iehara, Kyoto, Japan

Effective Administration and Management of Anti-GD2 Monoclonal Antibodies for Pediatric Neuroblastoma

Sponsored symposium by Y-mAbs

Introduction to symposium

Gudrun Schleiermacher, Paris, France

MS3.1 Clonal heterogeneity before treatment underlies spatial and temporal evolution in neuroblastoma

Gunes Gundem, New York, USA

MS3.2 Molecular diagnostics and targeted therapy of neuroblastoma in light of intratumour heterogeneity

Karin Schmelz, Berlin, Germany

MS3.3 Single cell DNA sequencing and sequential circulating tumor DNA analysis highlight intratumor genetic heterogeneity and clonal evolution under targeted therapies in neuroblastoma

Angela Bellini, Paris, France

MS3.4 Single-cell RNA-sequencing of peripheral neuroblastic tumors identifies an aggressive transitional cell state at the junction of an adrenergic-mesenchymal transdifferentiation trajectory

Daniel Carter, Randwick, Australia

Introduction to symposium

John Maris, Philadelphia, USA and Matthias Fischer, Cologne, Germany

MS4.1 The BRIP1 17q dependency gene in neuroblastoma: from fork stability to translation

Suzanne Vanhauwaert, Ghent, Belgium

MS4.2 A multi-omic surfaceome study identifies DLK1 as an epigenetically regulated protein and immunotherapeutic target in neuroblastoma

Amber Weiner, Philadelphia, USA

MS4.3 The evolution of MDM2 and MYCN amplifications in neuroblastoma

Caroline Rosswog, Cologne, Germany

MS4.4 The transcriptional co-repressor Runx1t1 is essential for N-myc-driven neuroblastoma tumorigenesis

Murray Norris, Kensington, Australia

This session is sponsored by Solving Kids Cancer

PA5.1 Single cell RNA-sequencing analysis of tumor heterogeneity and dynamic adaptive transcriptome changes in a MYCN driven zebrafish model

Lisa Depestel, Ghent, Belgium

PA5.2 Cross-talk between Tumor Associated Macrophages (TAM) and Cancer Associated Fibroblasts (CAF) in Neuroblastoma (NB) Contributes to a Pro-tumorigenic Microenvironment (TME) that Promotes TAM

Kevin Louault, Los Angeles, USA

PA5.3 Self-renewing neuroblastoma cells of the bone marrow share a mesenchymal phenotype which is associated with poor outcome: an NCRI CCL CSG Neuroblastoma Group Study

Susan Burchill, Leeds, UK

PA5.4 The landscape and evolution of somatic mutations captured in the NEPENTHE precision medicine clinical trial for relapsed high-risk neuroblastoma

Esther Berko, Philadelphia, USA

PA6.1 APR-246, which Restores p53 Function, is Highly Active against Alternative Lengthening of Telomere (ALT) Neuroblastoma Cell Lines and PDXs

Shawn Macha, Lubbock, USA

PA6.2 Integration of High-Throughput Drug Screening on Patient-Derived Organoids into the Princess Máxima Center iTHER Precision Medicine Program: The Future is Now!

Karin Langenberg, Utrecht, the Netherlands

PA6.3 Zero Childhood Cancer (ZERO): A comprehensive genomic, high-throughput drug screening and personalised xenograft modelling platform for high-risk cancer including relapsed/refractory high-risk neuroblastoma

Alvin Kamili & Toby Trahair, Sydney, Australia

PA6.4 Synergistic antitumor effects of combining selective CDK7 and BRD4 inhibition in neuroblastoma

Malgorzata Krajewska, Boston, USA

PA7.1 Combined blood and bone marrow cell-free DNA and disseminated tumor cell detection for sensitive response monitoring and early relapse detection in high-risk neuroblastoma patients

Sabine Taschner-Mandl, Vienna, Austria

PA7.2 Detection of actionable genetic alterations in cell-free DNA of neuroblastoma patients enrolled in the MAPPYACTS study

Gudrun Schleiermacher, Paris, France

PA7.3 Hypermethylated RASSF1A and tumor specific DNA breakpoints as circulating tumor markers for detection of minimal residual disease

Lieke Van Zogchel, Utrecht, the Netherlands

PA7.4 Combining genomics and ultra-sensitive bone marrow assessment for risk stratification in high-risk metastatic neuroblastoma: a HR-NBL1/SIOPEN study

Stefan Fiedler, Vienna, Austria

PA8.1 Leveraging an immunocompetent, MYCN-driven, non-germline GEM model for neuroblastoma and CyTOF mass cytometry to investigate immunosuppressive mechanisms and response to immunotherapy

Marie Menard, San Francisco, USA

PA8.2 Analysis of immune checkpoints in patients with high-risk neuroblastoma treated with dinutuximab beta with and without IL-2

Sascha Troschke-Meurer, Greifswald, Germany

PA8.3 The antibody-drug conjugate D3-GPC2-PBD is potently efficacious against diverse preclinical models of neuroblastoma and other cancers via engagement of a tumor-specific conformational GPC2 epitope

Kristopher Bosse, Philadelphia, USA

PA8.4 41BB or CD28 driven disialoganglioside (GD2)-specific CAR-T, but not T-cell engaging bispecific antibody, induces fatal neurotoxicity in mice

Brian Santich, New York, USA

Symposium: Stem cell mobilization and transplantation in pediatric oncology: lessons learned from clinical practice

Sponsored by Sanofi Genzyme

Introduction to symposium

Yael Mossé, Philadelphia, USA and Michelle Haber, Sydney, Australia

MS5.1 Phase 1 trial of Lorlatinib in patients with relapsed/refractory ALK-driven neuroblastoma

Kelly Goldsmith, Atlanta, USA

MS5.2 Arginine depletion therapy enhances efficacy of chemotherapy in delaying tumour development and increasing survival in the Th-MYCN mouse model of neuroblastoma

Ruby Pandher, Sydney, Australia

MS5.3 Targeting transcription-replication conflicts in MYCN-driven neuroblastoma

Gabriele Büchel, Wurzburg, Germany

MS5.4 Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma

Sally George, London, UK

This session is sponsored by St. Baldrick's Foundation

Introduction to symposium

Kimberly Stegmaier, Boston, USA and Rani George, Boston, USA

MS6.1 Extrachromosomal circular MYCN amplification: structure, regulation and genomic remodeling

Konstantin Helmsauer, Berlin, Germany

MS6.2 Three-dimensional analysis of MYCN function in neuroblastoma

Martin Eilers, Wurzburg, Germany

MS6.3 Distinct roles of noradrenergic core regulatory circuitry transcription factors in neuroblastoma cell identity

Isabelle Janoueix-Lerosey, Paris, France

MS6.4 Cell lineage predicts response to therapy in neuroblastoma

Rani George, Boston, USA

Introduction to symposium

Julie Park, Seattle, USA and Holger Lode, Greifswald, Germany

MS7.1 Academic, Phase I/II Trial on T Cells Expressing a Third-Generation GD2 Chimeric Antigen Receptor and Inducible Caspase-9 Safety Switch for Treatment of Relapsed/Refractory High-Risk Neuroblastoma

Francesca Del Bufalo, Rome, Italy

MS7.2 Pharmacodynamic effects of IL-2 in the treatment with a long-term infusion of anti-GD2 antibody dinutuximab beta: Role in outcome and toxicity in high-risk relapsed/refractory neuroblastoma patients. Results of a randomized SIOPEN-study

Holger Lode, Greifswald, Germany

MS7.3 The Composition, States and Dynamics of Microenvironmental Landscape of High-Risk Neuroblastoma Revealed by Single-Cell RNA Sequencing

Waleed Kholosy, Utrecht, the Netherlands

MS7.4 GD2 is a Macrophage Checkpoint Molecule and Combined GD2/CD47 Blockade Results in Synergistic Effects and Tumor Clearance in Xenograft Models of Neuroblastoma and Osteosarcoma

Robbie Majzner, Palo Alto, USA

PA9.1 The neuroblastoma dependency factor RRM2 is regulated during sympathoblast differentiation and represents a synergistic drug target for high-risk neuroblastoma

Carolina Nunes, Ghent, Belgium

PA9.2 The Yes-Associated Protein suppresses Harakiri to promote therapy resistance under tumor environmental stress in high-risk neuroblastoma

Jenny Shim, Atlanta, USA

PA9.3 Functional genomic screens identify the nuclear export factor NXT1 as a therapeutic target in MYCN-amplified neuroblastoma

Clare Malone, Boston, USA

PA9.4 Variations of DNA mismatch repair genes in hypermutated neuroblastoma

Audrey Petit, Paris, France

PA10.1 Adrenergic and Mesenchymal neuroblastoma cells have opposite resistance to ALK inhibitors and TRAIL, allowing dual therapy to impede resistance and relapse development

Ellen Westerhout, Amsterdam, the Netherlands

PA10.2 Activation of downstream signalling pathways is a mechanism of ALK inhibitor resistance in neuroblastoma

Mareike Berlak, Berlin, Germany

PA10.3 New therapeutic strategies for neuroblastoma: Targeting Gal-3BP with a highly potent Antibody-Drug Conjugate

Emily Capone, Chieti, Italy

PA10.4 The astatine-labeled PARP inhibitor [211At]MM4 induces complete and durable responses in neuroblastoma patient derived xenograft (PDX) models

Minu Samanta, Philadelphia, USA

PA11.1 Efficacious targeting of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy

Tao Liu, Kensington, Australia

PA11.2 SOX11 as guardian of epigenetic plasticity in neuroblastoma

Bieke Decaesteker, Ghent, Belgium

PA11.3 The neuroblastoma specific lincRNA NESPR controls noradrenergic cell identity and neuroblastoma cell survival

Eric James De Bony, Ghent, Belgium

PA12.1 Long-term follow-up of a Phase III Study of ch14.18 (Dinutuximab) Plus Cytokines for Patients with High-risk Neuroblastoma: Children’s Oncology Group Study ANBL0032

Alice Yu, San Diego, USA

PA12.2 A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma: An Update on Early Response and EFS

Wayne Furman, Memphis, USA

PA12.3 Haploidentical stem cell transplantation and subsequent immunotherapy with anti-GD2 antibody for patients with relapsed metastatic neuroblastoma

Tim Flaadt, Tuebingen, Germany

PA12.4 Discovery and Immunotherapeutic Targeting of Lineage-restricted Major Histocompatibility Complex (MHC) Antigens in Neuroblastoma

Mark Yarmarkovich, Philadelphia, USA

PA13.1 High Throughput Proteomic Profiling of the Cell Surfaceome Identifies PTK7 as a Novel Immunotherapeutic Candidate for Neuroblastoma

Kelly Goldsmith, Atlanta, USA

PA13.2 Particular poor treatment outcome of high-risk patients with low affinity FCGR2A/3A and IL-2-related high regulatory T cell levels during dinutuximab beta long-term infusion in two independent cohorts

Sascha Troschke-Meurer, Greifswald, Germany

PA13.3 Immune correlative markers in refractory or relapsed neuroblastoma patients treated with irinotecan/temozolomide/dinutuximab immunotherapy

Mitchell Diccianni, San Diego, USA

PA13.4 GD2-directed bispecific trifunctional antibody demonstrates therapeutic activity in a metastasized murine neuroblastoma model

Felix Zirngibl, Berlin, Germany

Parallel Symposium: Addressing Misinformation in Healthcare

Sponsored by Unit Therapeutics